Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto stocks push markets lower
Fri, 30 Jul 09:30 am

The Indian markets have started today's session on a weak note. The benchmark indices opened below the breakeven mark, and moved further into the negative territory. These have not managed to cut their losses since then. Other key Asian markets are in the red with Japan (down 1.5%) leading the pack of losers. The US markets closed lower by 0.3% yesterday. Currently in India, heavyweights from the BSE-Sensex are trading weak with auto and banking majors facing the brunt of selling activity. The BSE-Sensex is trading lower by around 70 points, while the NSE-Nifty is down by about 25 points. However, buying interest is being witnessed among mid and small cap stocks as the BSE-Midcap and BSE-Smallcap indices are trading higher by 0.4% each. The rupee is trading at 46.49 to the US dollar.

Pharma stocks have opened the day on a positive note. Gainers here include Sun Pharma and Ranbaxy. Lupin announced its 1QFY11 results yesterday. The company reported a topline growth of 21% YoY during the quarter, led by growth across all business segments. Formulation sales from the US and Europe registered a robust 40% YoY growth. In the US market especially, the branded generics business grew by 51% YoY, whereas the generics business grew by 45% YoY. Operating margins expanded by 2.3% during the quarter largely due to a fall in raw material costs (as percentage of sales). The company's net profits grew by a robust 40% YoY during the period led by the strong growth in operating profits, reduction in interest costs and lower tax expenses.

FMCG stocks have opened the day on a positive note. Gainers here include Dabur and Pidilite. As per a leading business daily, Dabur plans to raise Rs 20 bn for acquisitions. The amount is in addition to the funding for the recent Hobi Kozmetik deal. The company's board approved an enabling resolution for this fund-raising two weeks ago. It would be put to vote before the shareholders at the annual general meeting next month. This move comes at a time when organic growth in India is becoming very difficult and creating and building new brands is turning costly. Moreover, valuations abroad are very lucrative. As a result, the company is actively looking for acquisitions in healthcare and personal care after a gap of three years. It had acquired Fem Care Pharma in 2008 and Balsara Hygiene and Home Products in 2005.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks push markets lower". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.